Halil Yanardag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Halil Yanardag has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Tuncer Karayel
Department of Lung Diseases, Cerrahpaşa Medical Faculty, University of Istanbul, Istanbul, Turkey
7 shared publicationsSabriye Demirci
6 shared publications- Cuneyt Tetikkurt
İstanbul Cerrahpaşa University
5 shared publications Muammer Bilir
Istanbul University Cerrahpasa, Cerrahpasa Medical Faculty Department of Internal Medicine, Istanbul, Turkey
4 shared publicationsSedat Uygun
Department of Lung Diseases, Cerrahpaşa Medical Faculty, University of Istanbul, Istanbul, Turkey
4 shared publicationsEmre Yanardag
Istanbul University Institute of Health Sciences, Department of Immunology; University of Health Sciences Turkey, Istanbul Haseki Training and Research Hospital, Istanbul, Turkey
2 shared publications
Latest Publications
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1754
Serum D-dimer levels as an activity marker in sarcoidosis
Background: Coagulation and fibrinolytic systems have been implicated in the pathogenesis of sarcoidosis. D-dimer (DD), a fibrin breakdown product, can serve as a fibrinolytic activity marker. Objectives: Our aim in this study was to determine the correlation between DD levels and disease activity in sarcoidosis. Material and Methods: We retrospectively analyzed 66 patients with newly diagnosed sarcoidosis between 2000-2022. DD levels measured during the initial diagnosis. Diagnosis was made based on typical clinic appearance and/or histological finding of noncaseating granuloma. DD levels were measured turbidimetrically. Serum DD levels >500 ng/ml was considered positive. Patients were also evaluated with radiologic stage and spirometry. ESR, CRP, and ACE levels were also measured. Results: Of the 66 patients analyzed, 25 (37.8%) were DD (+). Radiology showed that six patients (9%) had stage 0, 22 (33.4%) had stage I, 24 (36.3%) had stage II, 14 (21.2%) had stage III disease. None had stage IV disease. DD positivity was correlated with disease stage. Of the 22 stage I patients, 12 (54.5%) were DD (+) and of 24 stage II patients 8 (33.4%) were DD (+). Among DD (+) patients, stage I and stage II disease was more common (83%). Median DLco was also found to be significantly lower in DD (+) patients; 75.4% in DD (+) patients and 89.9% in DD (-) patients. Serum ACE levels were also higher in DD (+) patients with a median of 84.3 IU/L, and a median of 44.7 IU/L in DD (-) patients. Conclusion: DD was frequently positive and DD positivity was found to be highly correlated with disease stage, lower DLco and elevated ACE levels. This implies that DD may be an useful marker for disease activity, but further studies are required.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1754
Serum D-dimer levels as an activity marker in sarcoidosis
Background: Coagulation and fibrinolytic systems have been implicated in the pathogenesis of sarcoidosis. D-dimer (DD), a fibrin breakdown product, can serve as a fibrinolytic activity marker. Objectives: Our aim in this study was to determine the correlation between DD levels and disease activity in sarcoidosis. Material and Methods: We retrospectively analyzed 66 patients with newly diagnosed sarcoidosis between 2000-2022. DD levels measured during the initial diagnosis. Diagnosis was made based on typical clinic appearance and/or histological finding of noncaseating granuloma. DD levels were measured turbidimetrically. Serum DD levels >500 ng/ml was considered positive. Patients were also evaluated with radiologic stage and spirometry. ESR, CRP, and ACE levels were also measured. Results: Of the 66 patients analyzed, 25 (37.8%) were DD (+). Radiology showed that six patients (9%) had stage 0, 22 (33.4%) had stage I, 24 (36.3%) had stage II, 14 (21.2%) had stage III disease. None had stage IV disease. DD positivity was correlated with disease stage. Of the 22 stage I patients, 12 (54.5%) were DD (+) and of 24 stage II patients 8 (33.4%) were DD (+). Among DD (+) patients, stage I and stage II disease was more common (83%). Median DLco was also found to be significantly lower in DD (+) patients; 75.4% in DD (+) patients and 89.9% in DD (-) patients. Serum ACE levels were also higher in DD (+) patients with a median of 84.3 IU/L, and a median of 44.7 IU/L in DD (-) patients. Conclusion: DD was frequently positive and DD positivity was found to be highly correlated with disease stage, lower DLco and elevated ACE levels. This implies that DD may be an useful marker for disease activity, but further studies are required.
- Open Access
- 10 September 2019
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 89 (3)
Carpal tunnel syndrome associated with sarcoidosis in identical twin patients
Sarcoidosis is a multisystemic disease that may lead to neurologic complications in 10% of the patients. Carpal tunnel syndrome is very rare in sarcoidosis. We present two identical twin sarcoidosis patients with carpal tunnel syndrome. A number of factors may cause carpal tunnel syndrome like wrist anatomy, occupation, diabetes, rheumatoid arthritis, pregnancy and renal failure. Although the above factors do not directly cause carpal tunnel syndrome, they may increase your chances of developing or aggravate median nerve damage as it is in sarcoidosis. Sarcoidosis relevant neuropathy and granulomas may be the primary mechanism of sarcoidosis associated carpal tunnel syndrome. Although rare, carpal tunnel syndrome may be a feature of sarcoidosis that may lead to irreversible damage in cases of delayed diagnosis. The presence of this syndrome in identical twin patients may shed light into the pathogenesis and the genetic transmission of sarcoidosis with the associated carpal tunnel syndrome.
- 10 September 2019
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 89 (3)
Open AccessCarpal tunnel syndrome associated with sarcoidosis in identical twin patients
Sarcoidosis is a multisystemic disease that may lead to neurologic complications in 10% of the patients. Carpal tunnel syndrome is very rare in sarcoidosis. We present two identical twin sarcoidosis patients with carpal tunnel syndrome. A number of factors may cause carpal tunnel syndrome like wrist anatomy, occupation, diabetes, rheumatoid arthritis, pregnancy and renal failure. Although the above factors do not directly cause carpal tunnel syndrome, they may increase your chances of developing or aggravate median nerve damage as it is in sarcoidosis. Sarcoidosis relevant neuropathy and granulomas may be the primary mechanism of sarcoidosis associated carpal tunnel syndrome. Although rare, carpal tunnel syndrome may be a feature of sarcoidosis that may lead to irreversible damage in cases of delayed diagnosis. The presence of this syndrome in identical twin patients may shed light into the pathogenesis and the genetic transmission of sarcoidosis with the associated carpal tunnel syndrome.
- Open Access
- 29 January 2018
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 88 (1) , 67-71
Clinical and prognostic significance of muscle biopsy in sarcoidosis
The main objective of this study was to evaluate the influence of muscle involvement on the clinical features, prognostic outcome, extrapulmonary organ, and endobronchial involvement in sarcoidosis patients. The second aim was to assess the diagnostic yield of muscle biopsy for the histopathologic identification of sarcoidosis. Â Fifty sarcoidosis patients participated in the study. The patients were classified into two groups according to the histopathologic presence of non-caseating granulomatous inflammatory pattern of the muscle biopsy samples and were evaluated retrospectively in regard to clinical features, prognosis, extrapulmonary, and endobronchial disease involvement. Pathologic examination of the muscle biopsy samples revealed non-caseating granulomas in eighteen and myositis in seven patients compatible with sarcoidosis. The diagnostic yield of muscle biopsy for demonstrating non-caseating granulomatous inflammation was fifty percent. Patients with muscle sarcoidosis showed a worse prognosis and a more severe extrapulmonary organ involvement than the patients without muscle disease. Muscle biopsy was not statistically significant to delineate diffuse endobronchial involvement while it was suggestive for endobronchial disease clinically. The results of our study reveal that muscle biopsy appears to be a useful diagnostic tool along with its safety and easy clinical applicability. It is a rewarding utility to predict the prognostic outcome and extrapulmonary involvement in sarcoidosis patients. Positive biopsy on the other hand confirms the identification of sarcoidosis in patients with single organ involvement carrying an equivocal diagnostic clinical pattern. Muscle biopsy may be considered as the initial step for the final diagnosis of sarcoidosis in such cases.
- 29 January 2018
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 88 (1) , 67-71
Open AccessClinical and prognostic significance of muscle biopsy in sarcoidosis
The main objective of this study was to evaluate the influence of muscle involvement on the clinical features, prognostic outcome, extrapulmonary organ, and endobronchial involvement in sarcoidosis patients. The second aim was to assess the diagnostic yield of muscle biopsy for the histopathologic identification of sarcoidosis. Â Fifty sarcoidosis patients participated in the study. The patients were classified into two groups according to the histopathologic presence of non-caseating granulomatous inflammatory pattern of the muscle biopsy samples and were evaluated retrospectively in regard to clinical features, prognosis, extrapulmonary, and endobronchial disease involvement. Pathologic examination of the muscle biopsy samples revealed non-caseating granulomas in eighteen and myositis in seven patients compatible with sarcoidosis. The diagnostic yield of muscle biopsy for demonstrating non-caseating granulomatous inflammation was fifty percent. Patients with muscle sarcoidosis showed a worse prognosis and a more severe extrapulmonary organ involvement than the patients without muscle disease. Muscle biopsy was not statistically significant to delineate diffuse endobronchial involvement while it was suggestive for endobronchial disease clinically. The results of our study reveal that muscle biopsy appears to be a useful diagnostic tool along with its safety and easy clinical applicability. It is a rewarding utility to predict the prognostic outcome and extrapulmonary involvement in sarcoidosis patients. Positive biopsy on the other hand confirms the identification of sarcoidosis in patients with single organ involvement carrying an equivocal diagnostic clinical pattern. Muscle biopsy may be considered as the initial step for the final diagnosis of sarcoidosis in such cases.
- Open Access
- 22 September 2017
- Published by PAGEPress Publications
- Vol. 87 (3) , 79-84
Association of HLA antigens with the clinical course of sarcoidosis and familial disease
Patients with sarcoidosis usually have a benign course and a favourable prognosis. Although spontaneous remission is common, a progressive disease with a severe prognosis occurs in a small but significant number of patients. The aim of this study was to evaluate the potential significance of HLA antigens as a clinical marker on the outcome of sarcoidosis patients. We conducted a retrospective cohort study for HLA class I and II allels in 74 sarcoidosis patients and 72 healthy transplant donors. Bronchoscopy and bronchial biopsies were performed in each patient. Two or more positive bronchial biopsy samples revealing granulomatous inflammation was defined as diffuse while one positive biopsy sample was considered as limited endobronchial disease. Three or more extrapulmonary organ involvement was denoted as severe extrapulmonary disease. The patients were followed-up at least for eight years. Incidence of progressive disease was significantly high in patients with positive HLA-DRB1*07, DRB1*14 (p<0.05) and DRB1*15 (p <0.001) allels. HLA-DRB1*14 and DRB1*15 were associated with severe extrapulmonary organ involvement (p<0.001). HLA-DRB1 *14 (p<0.05) and DRB1*15 (p<0.001) were significantly more frequent in patients with diffuse endobronchial involvement. Incidence of familial disease was 14.8% with a 6.7% identical HLA typing. Presence of HLA class I and II allels may influence the severity and prognosis of sarcoidosis significantly. Apart from defining genetic susceptibility, HLA class I and class II allels appear to be relevant and crucial markers for the to predict the clinical outcome of sarcoidosis. Distinct heterogenity of sarcoidosis may arise from the particular presence of different allels in invidual patients.
- 22 September 2017
- Published by PAGEPress Publications
- Vol. 87 (3) , 79-84
Open AccessAssociation of HLA antigens with the clinical course of sarcoidosis and familial disease
Patients with sarcoidosis usually have a benign course and a favourable prognosis. Although spontaneous remission is common, a progressive disease with a severe prognosis occurs in a small but significant number of patients. The aim of this study was to evaluate the potential significance of HLA antigens as a clinical marker on the outcome of sarcoidosis patients. We conducted a retrospective cohort study for HLA class I and II allels in 74 sarcoidosis patients and 72 healthy transplant donors. Bronchoscopy and bronchial biopsies were performed in each patient. Two or more positive bronchial biopsy samples revealing granulomatous inflammation was defined as diffuse while one positive biopsy sample was considered as limited endobronchial disease. Three or more extrapulmonary organ involvement was denoted as severe extrapulmonary disease. The patients were followed-up at least for eight years. Incidence of progressive disease was significantly high in patients with positive HLA-DRB1*07, DRB1*14 (p<0.05) and DRB1*15 (p <0.001) allels. HLA-DRB1*14 and DRB1*15 were associated with severe extrapulmonary organ involvement (p<0.001). HLA-DRB1 *14 (p<0.05) and DRB1*15 (p<0.001) were significantly more frequent in patients with diffuse endobronchial involvement. Incidence of familial disease was 14.8% with a 6.7% identical HLA typing. Presence of HLA class I and II allels may influence the severity and prognosis of sarcoidosis significantly. Apart from defining genetic susceptibility, HLA class I and class II allels appear to be relevant and crucial markers for the to predict the clinical outcome of sarcoidosis. Distinct heterogenity of sarcoidosis may arise from the particular presence of different allels in invidual patients.
- Open Access
- 1 January 2013
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 8 (1) , 26
Diagnosis of cutaneous sarcoidosis; clinical and the prognostic significance of skin lesions
Sarcoidosis is a systemic disease characterized by the formation of noncaseating granulomas in various tissues. Cutaneous involvement occurs in 20 to 35 percent of the patients and may be the initial manifestation of the disease. Our study was performed to discriminate the clinical, laboratory, and prognostic differences between patients with specific and nonspecific cutaneous involvement. The second aim was to asses the diagnostic usefulness of punch biopsy in sarcoidosis.
- 1 January 2013
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 8 (1) , 26
Open AccessDiagnosis of cutaneous sarcoidosis; clinical and the prognostic significance of skin lesions
Sarcoidosis is a systemic disease characterized by the formation of noncaseating granulomas in various tissues. Cutaneous involvement occurs in 20 to 35 percent of the patients and may be the initial manifestation of the disease. Our study was performed to discriminate the clinical, laboratory, and prognostic differences between patients with specific and nonspecific cutaneous involvement. The second aim was to asses the diagnostic usefulness of punch biopsy in sarcoidosis.
- Open Access
- 1 January 2012
- Published by LookUs Bilisim A.S. in Turkish Journal of Hematology
- Vol. 29 (3) , 217-222
Pulmonary Radiological Findings in Patients with Acute Myeloid Leukemia and Their Relationship to Chemotherapy and Prognosis: A Single-Center Retrospective Study
- 1 January 2012
- Published by LookUs Bilisim A.S. in Turkish Journal of Hematology
- Vol. 29 (3) , 217-222
Open AccessPulmonary Radiological Findings in Patients with Acute Myeloid Leukemia and Their Relationship to Chemotherapy and Prognosis: A Single-Center Retrospective Study
- Open Access
- 1 January 2007
- Published by Wiley in Canadian Respiratory Journal
- Vol. 14 (4) , 209-211
Diagnostic Value of Peripheral Lymph Node Biopsy in Sarcoidosis: A Report of 67 Cases
A peripheral lymph node (PLN) 1 cm or greater was found in 79 of 546 sarcoidosis patients (14.5%) between 1972 and 2005. Seventy‐two of the 79 sarcoidosis patients had a lymph node biopsy performed. Sixty‐seven of these biopsy specimens were histologically diagnosed as sarcoidosis, whereas five patients had a reactive adenopathy. For patients with histological diagnosis of sarcoidosis, localizations of the biopsies were as follows: cervical (n=21), supra‐clavicular (n=20), inguinal (n=11), axillary (n=8), epitrochlear (n=5) and submandibular (n=2). At the time of biopsy, 12 patients had stage 0 disease, 37 patients had stage I disease, 14 patients had stage II disease and four patients had stage III disease. Skin involvement (16.4%) was the most frequently observed type of organ involvement in patients who had enlarged PLNs due to sarcoidosis. In the presence of an enlarged PLN in sarcoidosis, biopsy had a greater diagnostic value compared with other methods, as well as having a relatively low cost (approximately US$120) in Turkey. No procedure‐related complications were observed. In conclusion, it is recommended that PLNs be thoroughly examined when sarcoidosis is suspected. If an enlarged PLN is found, biopsy should be routinely performed because it is an easy, convenient and practical method, with a low complication risk and a high sensitivity.
- 1 January 2007
- Published by Wiley in Canadian Respiratory Journal
- Vol. 14 (4) , 209-211
Open AccessDiagnostic Value of Peripheral Lymph Node Biopsy in Sarcoidosis: A Report of 67 Cases
A peripheral lymph node (PLN) 1 cm or greater was found in 79 of 546 sarcoidosis patients (14.5%) between 1972 and 2005. Seventy‐two of the 79 sarcoidosis patients had a lymph node biopsy performed. Sixty‐seven of these biopsy specimens were histologically diagnosed as sarcoidosis, whereas five patients had a reactive adenopathy. For patients with histological diagnosis of sarcoidosis, localizations of the biopsies were as follows: cervical (n=21), supra‐clavicular (n=20), inguinal (n=11), axillary (n=8), epitrochlear (n=5) and submandibular (n=2). At the time of biopsy, 12 patients had stage 0 disease, 37 patients had stage I disease, 14 patients had stage II disease and four patients had stage III disease. Skin involvement (16.4%) was the most frequently observed type of organ involvement in patients who had enlarged PLNs due to sarcoidosis. In the presence of an enlarged PLN in sarcoidosis, biopsy had a greater diagnostic value compared with other methods, as well as having a relatively low cost (approximately US$120) in Turkey. No procedure‐related complications were observed. In conclusion, it is recommended that PLNs be thoroughly examined when sarcoidosis is suspected. If an enlarged PLN is found, biopsy should be routinely performed because it is an easy, convenient and practical method, with a low complication risk and a high sensitivity.
- 17 May 2006
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 134 (5) , 848-851
Upper respiratory tract involvement of sarcoidosis in the Turkish population
PRINCIPLES AND METHODS: Upper respiratory tract (URT) involvement is rare in sarcoidosis. In this descriptive study, we retrospectively evaluated the clinical and demographic features of 12 (2.19%) patients with URT involvement out of the 546 sarcoidosis patients with follow‐up visits at our center within the last 40‐year period.RESULTS: Out of the 546 patients, 12 (2.19%) had upper respiratory tract involvement, 5 (0.91%) had laryngeal involvement, 4 (0.73%) had sinonasal tract involvement, 2 (0.36) patients had salivary gland involvement, and 1 patient had tonsillary involvement. The number of stage 0 subjects among other sarcoidosis patients was significantly lower than that among those with URT involvement.CONCLUSIONS: URT involvement is rarely diagnosed in patients with systemic sarcoidosis. The most common site for URT involvement among the Turkish population is the larynx, followed by the sinonasal tract.EBM rating: C‐4
- 17 May 2006
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 134 (5) , 848-851
Upper respiratory tract involvement of sarcoidosis in the Turkish population
PRINCIPLES AND METHODS: Upper respiratory tract (URT) involvement is rare in sarcoidosis. In this descriptive study, we retrospectively evaluated the clinical and demographic features of 12 (2.19%) patients with URT involvement out of the 546 sarcoidosis patients with follow‐up visits at our center within the last 40‐year period.RESULTS: Out of the 546 patients, 12 (2.19%) had upper respiratory tract involvement, 5 (0.91%) had laryngeal involvement, 4 (0.73%) had sinonasal tract involvement, 2 (0.36) patients had salivary gland involvement, and 1 patient had tonsillary involvement. The number of stage 0 subjects among other sarcoidosis patients was significantly lower than that among those with URT involvement.CONCLUSIONS: URT involvement is rarely diagnosed in patients with systemic sarcoidosis. The most common site for URT involvement among the Turkish population is the larynx, followed by the sinonasal tract.EBM rating: C‐4
- 26 April 2006
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 54 (03) , 198-201
Clinical Value of Mediastinoscopy in the Diagnosis of Sarcoidosis: An Analysis of 68 Cases
Mediastinoscopy was performed for confirmation of the diagnosis in 68 patients who were suspected clinically and radiologically of having sarcoidosis. In 66 of 68 cases in which mediastioscopy was performed a diagnosis was attained. In 35 cases, endobronchial biopsy was performed by bronchoscopy. In only 5 of these (14.2 %) was the diagnosis of sarcoidosis confirmed. The sensitivity of mediastinoscopy was remarkably superior compared with that of endobronchial biopsy. No complication developed with either mediastinoscopy or endobronchial biopsy. In Turkey, mediastinoscopy without any complication costs about 650 USD while bronchoscopy and endobronchial biopsy cost about 150 USD. In our study in which we looked for a histological confirmation - in the cases suspected of sarcoidosis - mainly through mediastinoscopy and rarely through other methods (i.e., endobronchial biopsy in one case, skin biopsy in another), we did not come up with a different diagnosis. Therefore, patients suspected of having sarcoidosis should undergo a careful clinical, laboratory, and radiologic examination; they should be under continuous close observation; when necessary (e.g., skin and lip biopsy), the tissue diagnosis should be made by other methods, but if there is the possibility of a disease such as tuberculosis and lymphoma, mediastinoscopy should be performed. The diagnosis of stage 3 sarcoidosis is difficult. For diagnosis, sometimes videothoracoscopy or explorative thoracotomy may be necessary. However, in all our 3 cases with stage 3, we reached the diagnosis of sarcoidosis by the less invasive and less expensive method of mediastinoscopy. Despite our small number of cases, we believe that mediastinoscopy is a very important instrument for diagnosis of stage 3 sarcoidosis.
- 26 April 2006
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 54 (03) , 198-201
Clinical Value of Mediastinoscopy in the Diagnosis of Sarcoidosis: An Analysis of 68 Cases
Mediastinoscopy was performed for confirmation of the diagnosis in 68 patients who were suspected clinically and radiologically of having sarcoidosis. In 66 of 68 cases in which mediastioscopy was performed a diagnosis was attained. In 35 cases, endobronchial biopsy was performed by bronchoscopy. In only 5 of these (14.2 %) was the diagnosis of sarcoidosis confirmed. The sensitivity of mediastinoscopy was remarkably superior compared with that of endobronchial biopsy. No complication developed with either mediastinoscopy or endobronchial biopsy. In Turkey, mediastinoscopy without any complication costs about 650 USD while bronchoscopy and endobronchial biopsy cost about 150 USD. In our study in which we looked for a histological confirmation - in the cases suspected of sarcoidosis - mainly through mediastinoscopy and rarely through other methods (i.e., endobronchial biopsy in one case, skin biopsy in another), we did not come up with a different diagnosis. Therefore, patients suspected of having sarcoidosis should undergo a careful clinical, laboratory, and radiologic examination; they should be under continuous close observation; when necessary (e.g., skin and lip biopsy), the tissue diagnosis should be made by other methods, but if there is the possibility of a disease such as tuberculosis and lymphoma, mediastinoscopy should be performed. The diagnosis of stage 3 sarcoidosis is difficult. For diagnosis, sometimes videothoracoscopy or explorative thoracotomy may be necessary. However, in all our 3 cases with stage 3, we reached the diagnosis of sarcoidosis by the less invasive and less expensive method of mediastinoscopy. Despite our small number of cases, we believe that mediastinoscopy is a very important instrument for diagnosis of stage 3 sarcoidosis.